Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals ...

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options ...

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

Adult-onset Still's Disease (AOSD) is a rare, systemic inflammatory disorder characterized by high fevers, rashes, and arthritis, impacting adults wi ...